“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra
From Washington, DC
- Roll Call reports,
- “President Donald Trump said Friday he might get more accomplished with Democrats running the House and Senate than he did in a Republican-led Congress, but his legislative to-do list differs significantly from the incoming majority party.
- “After previously suggesting he could strike a bipartisan immigration deal with Democrats, Trump on Friday added several items to his wish list after returning Thursday night from a swing across Asia, including several that have support with Democrats with whom he’s bitterly clashed before.
- “Speaking in a stuffy James A. Brady Briefing Room for just shy of 90 minutes, the GOP president contended, without naming a single Democratic leader or lawmaker, that members of the opposition party have called him “about two things in particular,” pointing to health care and immigration.”
- and
- “House Democrats unveiled a 2027 legislative calendar Friday that includes 33 voting weeks, as the incoming majority party looks to pass an ambitious agenda following massive midterm election wins.
- “According to the calendar released by soon-to-be House Majority Leader Katherine M. Clark, the chamber would convene for the first session of the 120th Congress with a rare Sunday gathering on Jan. 3. The first votes of the year would take place that week.
- “House Democrats are hitting the ground running on January 3,” the Massachusetts Democrat said in a statement. “This calendar reflects the scale and urgency of our work ahead. Americans voted for a Majority that will move decisively to lower costs, protect healthcare, and hold the crooks accountable. Whether we’re working in DC or in our districts, that’s exactly what we’re going to do.”
- “In most months, the House will be in session for three weeks, with the exception of the annual August recess. That will be followed by four consecutive weeks of voting in September.
- “The calendar also includes a two-week break for Easter in March, while the Fourth of July falls on a Sunday.”
- Per Department of Health and Human Services news release,
- “The Centers for Medicare & Medicaid Services (CMS) today issued a proposed rule that is intended to revitalize competition in Medicare Advantage (MA) and Part D and give seniors more meaningful choices in how they receive care. If finalized, the proposed policy updates, alongside a new CMS Innovation Center (CMMI) model, would break down administrative barriers for new market entrants, elevate prevention through nutrition to improve MA seniors’ health outcomes, and pioneer localized care innovations.
- “Medicare food benefits should pay for nutritious food that helps people improve their health and manage chronic disease,” said HHS Secretary Robert F. Kennedy, Jr. “This proposal would require those benefits to meet the Dietary Guidelines for Americans while preserving access to foods and nutritional products that providers recommend for patients’ specific medical needs. Under President Trump, we are putting prevention at the center of health care and demanding more from every Medicare dollar.”
- “People with Medicare should be able to choose coverage based on what matters most to them — quality, affordability, and access,” said CMS Administrator Dr. Mehmet Oz. “These proposals are about creating a Medicare Advantage marketplace that rewards better care and better value while empowering beneficiaries with the options and knowledge they need to make informed decisions about their health.” * * *
- “CMS is issuing an accompanying Request for Information (RFI) seeking input for future exploration to further expand primary care networks and utilize innovative technologies like Super Intelligence (also called Artificial Intelligence).
- “The proposed rule will be open for public comment for 60 days following publication in the Federal Register here.
- “For more information, please view the Fact Sheet here.”
- and
- “The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), today announced $47 million in awards to 15 organizations to test new approaches to chronic disease prevention and management for people with Medicare. Through the Make America Healthy Again: Enhancing Lifestyle and Evaluating Value-based Approaches Through Evidence (MAHA ELEVATE) Model, recipients will test functional or lifestyle medical interventions that complement conventional medical care. The model will evaluate whether these approaches improve quality of care and reduce costs.
- “President Trump has directed us to Make America Healthy Again, and that means putting prevention at the center of health care,” said HHS Secretary Robert F. Kennedy, Jr. “Through MAHA ELEVATE, we will test approaches to preventing and managing chronic disease, measure whether they improve health and lower costs, and demand evidence of results for patients and taxpayers.”
- “For too long, our health system has treated chronic disease after it takes hold, instead of helping people prevent it in the first place,” said CMS Administrator Dr. Mehmet Oz. “With these awards, we are putting promising approaches to the test for people with Medicare. We will measure what helps them build healthier habits, manage chronic conditions, and stay active, as well as what delivers value for patients and taxpayers.” * * *
- “CMS also plans to publish a new Notice of Funding Opportunity for up to 15 additional awards in 2027.
- “Read the Fact Sheet here [PDF, 670 KB].
- “For a full list of awardees, project summaries and details about the MAHA ELEVATE Model, visit: https://www.cms.gov/priorities/innovation/innovation-models/maha-elevate“
- and
- “The U.S. Department of Health and Human Services (HHS), through its Office of Minority Health (OMH), has awarded $2 million in grants to two organizations to expand the Center for Indigenous Innovation and Health (CIIH). Over two years, the awards will support outreach, education, and partnerships to prevent chronic disease and improve health outcomes in American Indian and Alaska Native communities.
- “The awards were highlighted during HHS’ November 17–18 Traditional Food Summit, which focused on strengthening Tribal food systems and integrating traditional foods into health programs and policies. The two-day summit featured panel discussions, cultural presentations, demonstrations, storytelling, and opportunities for dialogue.”
- The American Medical Association News tells us,
- “The AHA Nov. 20 responded to a request for information from the Centers for Disease Control and Prevention on data intermediaries and ways to improve public health data exchange. In its comments, the AHA recommended that the CDC ensure data intermediaries reduce inappropriate variability; that frameworks support and complement existing data exchange capabilities such as the Trusted Exchange Framework and Common Agreement, Health Information Exchanges and Qualified Health Information Networks; and that the agency aligns incentives and supports infrastructure investment, particularly for rural and critical access hospitals. The AHA also requested the agency prioritize the privacy and security of patient data while exploring opportunities for public health data exchange modernization; synchronize efforts with the Office of the National Coordinator and the Centers for Medicare & Medicaid Services to ensure alignment of standards and timelines; and leverage lessons learned from electronic case reporting.”
- Fierce Healthcare informs us,
- “The Trump administration has agreed to withdraw its moratorium on new broker enrollments, court documents show.
- “According to a filing submitted Thursday, the Centers for Medicare & Medicaid Service will published a withdrawal on the Federal Register. The move follows a court ruling earlier this month in favor of two leading organizations representing brokers, which granted a preliminary injunction on the moratorium.”
From the U.S. Office of Personnel Management front,
- Govexec reports,
- “A coalition of nearly 40 labor unions, representing workers in both private and public sectors, called on Congress Thursday to institute a 3.8% pay raise for federal workers in 2027 when it advances legislation to keep the government open past Dec. 11.
- “Earlier this year, President Trump proposed freezing federal employee compensation at 2026 levels next year, all while proposing raises of between 5 and 7% for military service members and instructing the Office of Personnel Management to increase federal law enforcement officer pay by 3.8% in January using special pay rate authorities.
- “Though Republicans control both chambers of Congress, employee groups hope that Democrats’ success in the midterm elections earlier this month will grant them greater leverage to override the president’s pay plan before it is implemented in January.”
- FedSmith adds, “Unions cite a 25% federal pay gap while the average federal salary tops $111,000. Here’s what each figure really says about your pay.”
From the U.S. Food and Drug Administration front
- Beckers Hospital Review warns,
- “Medline has updated its repair and replace program for Medline Brand beds and accessories after receiving reports of seven deaths and 35 serious injuries as of Nov. 8, according to a Nov. 13 update from Medline posted by the FDA.
- “On Oct. 14, the company issued a product recall, market exit and discontinuation of all Medline Brand beds, rails, mattresses and accessories due to potential fire hazards and entrapment risk. On Oct. 29, the FDA issued an early alert involving all Medline Brand beds and associated components after Medline reported two deaths and 16 serious injuries.
- “Until a bed is repaired or replaced, Medline has advised users to unplug the bed from the outlet and plug it in only when repositioning a patient, avoid using extension cords, and have a second person help use and move the bed whenever possible.”
- Cardiovascular Business reports,
- “The U.S. Food and Drug Administration (FDA) is warning the public about a new recall involving specific lots of multiple vascular guidewires.
- “The devices in question are the Navilyst Vascular Guidewire, Spectrum Vascular Guidewire and Arrow Marked Guidewire manufactured by Minnesota-based Heraeus Medevio. They were built to help interventional cardiologists, interventional radiologists and other clinicians enter a patient’s peripheral blood vessels during minimally invasive procedures.
- “This is an Early Alert communication, which means the FDA is still reviewing the issue. Once its investigation is done, the agency will confirm the severity of this recall.”
- Radiology Business relates,
- “The U.S. Food and Drug Administration (FDA) has cleared new software from Siemens Healthineers for the detailed management of coronary artery disease (CAD) and percutaneous coronary intervention (PCI) planning.
- “Syngo.CT Coronary Cockpit uses coronary computed tomography angiography (CCTA) data to give clinicians an advanced, automated analysis of a patient’s coronary plaque that is designed to help clinical decision-making and streamline workflow efficiency across the CAD care pathway. The software is compatible with CCTA data from any vendor’s CT scanner.
- “With Syngo.CT Coronary Cockpit, clinicians can obtain advanced insights from a patient’s CT scan to support a more comprehensive assessment of cardiac health and better inform treatment decisions, ultimately helping people with coronary artery disease live longer, healthier lives,” said Olivia Egan, head of CT at Siemens Healthineers North America, in a statement.”
- Med Tech Dive adds,
- “Zimmer Biomet has filed for 510(k) clearance for an autonomous version of its Monogram orthopedic robot, a company spokesperson told MedTech Dive in an email.
- “CEO Ivan Tornos said at an investor event this week that Zimmer made the filling on Monday and hopes to receive Food and Drug Administration clearance sometime next year.
- “Tornos said he expects Monogram to be a “game-changing platform,” citing the robot’s safety, efficiency, ease of use and accuracy.”
- Beckers Hospital Review tells us,
- “The FDA has extended its review of Belite Bio’s experimental eye disease drug tinlarebant by three months, moving its decision deadline to May 12, 2027.
- “The agency needs additional time to evaluate information supporting the drug’s application for Stargardt disease type 1, an inherited retinal disorder, according to a Nov. 20 news release.
- “If the FDA identifies no major deficiencies during its ongoing review, it plans to communicate proposed labeling changes and any anticipated postmarketing requirements by April 12, 2027.
- “Tinlarebant is an oral treatment designed to slow the buildup of vitamin A-related toxins that contribute to retinal damage.”
- and
- “The FDA has established a CBER Safety Council within its Center for Biologics Evaluation and Research to strengthen oversight of vaccines, gene and cell therapies and blood products after they reach the market, the agency announced Nov. 19. The council took effect that day.
- “The council will report directly to the center’s director and be separate from the product offices that review and approve the therapies, according to the FDA’s announcement. It replaces CBER’s longtime Safety Working Group. The FDA said the change is meant to ensure that postmarket safety oversight is done by a dedicated, cross-functional team with clear accountability.
- “The council will review postmarket safety signals across all CBER-regulated products, conduct benefit-risk assessments and recommend regulatory actions, including safety-related market withdrawals, according to the FDA. Its work will cover emerging safety concerns, potential labeling changes, risk-management measures and safety-related postmarket studies, and it will coordinate with the CDC and NIH using surveillance systems including the Vaccine Adverse Event Reporting System and the FDA’s Sentinel program. The FDA said it will release more details on the council’s structure and membership later.”
No Surprises Act News,
- Beckers Payer Issues lets us know,
- “HHS and the Labor and Treasury departments launched the Independent Dispute Resolution Gateway Nov. 13, a centralized platform for managing payment disputes under the federal independent dispute resolution process.
- The article offers four things to know about the gateway.
From the judicial front,
- Fierce Healthcare reports,
- “UnitedHealth Group is joining the ranks of insurers that are suing the feds over the 2027 Medicare Advantage star ratings calculations.
- “Much like other recent lawsuits, the healthcare giant argues that the Centers for Medicare & Medicaid Services inappropriately used multiple measures in the calculations. Over the summer, a Georgia federal court sided with MA plan Clover Health, and tossed 20 measures that were used in its 2026 scores.”
- MedPage Today relates,
- “Agrochemical maker Bayer will pay up to $7.25 billion over two decades to resolve thousands of claims from U.S. cancer patients asserting the company should have warned people that its popular weedkiller Roundup could cause lymphoma, according to a settlement approved Friday by a Missouri judge.
- “The nationwide settlement applies both to Roundup users who already are ill and those who become diagnosed with non-Hodgkin lymphoma in future years. Participants could get an average of between $10,000 and $165,000, depending on how they used the product, how old they were when diagnosed, and the severity of their illness.”
From the public health and medical / Rx research front,
- The Centers for Disease Control and Prevention announced today,
- “COVID-19, flu, and RSV are key indicators of overall respiratory illness activity
- “The amount of acute respiratory illness causing people to seek health care is low but increasing.
- “RSV activity is low in most areas of the country.
- “COVID-19 activity is low nationally.
- “Seasonal flu activity continues to increase in many parts of the country.
- “Rhinovirus/Enterovirus (RV/EV) is elevated nationally but declining. Respiratory adenovirus (HAdV) is elevated and increasing in some regions of the country.”
- The University of Minnesota’s CIDRAP adds,
- “The share of Americans seeking healthcare for flulike symptoms continues to rise amid an early flu season.
- “The proportion of outpatients for influenza-like-illness (ILI) for the week ending November 14 was 3.8%, up from 3.2% the previous week and above the national baseline of 2.9% for the second consecutive week, the Centers for Disease Control and Prevention (CDC) said today in its weekly FluView update. ILI activity increased in all regions of the country except for the Northeast, and in all age-groups, compared with the previous week.
- “While test positivity remained flat at 11.8%, the influenza-associated hospital admission rate rose to 3.5 per 100,000 population, with the highest hospitalization rate seen in adults age 65 and over, followed by the 0 to 4 and 50 to 64-year age groups. The CDC also reported two more flu-related deaths in children, bringing the season total to seven, and a pediatric death from the 2025-26 flu season, bring that season’s total to 204 deaths.
- “Of the viruses reported by public health laboratories, 99% have been influenza A.”
- and
- “On the heels of measles being declared endemic in the United States, the Centers for Disease Control and Prevention (CDC) reported the largest one-week jump in measles cases in decades. With 426 new infections of the airborne virus, the national total now stands at 5,838 infections. This marks the 15th straight week of a triple-digit increase in the US measles total.
- “Nearly six in 10 measles patients are children or teens, and 96% of cases are among people who are unvaccinated or don’t know their vaccination status. Two doses of the measles vaccine are 97% effective at preventing infection.
- “It is tragic and unnecessary when people suffer or die from vaccine-preventable diseases, said New York State Health Commissioner James McDonald, MD, MPH, in a press release from the Association of State and Territorial Health Officials, of which he is a board member.
- “We know vaccines work. We have the science. What we need now is the leadership and commitment to use them,” he said.
- “The year’s measles hospitalization rate remains at 11%, the same as in 2025.”
- The American Hospital Association News reports,
- “The University of South Carolina Rural Health Research Center recently published a study examining differences in rural and urban child health across the United States. Among the findings, rural children are more likely than urban children to experience certain health risk factors, including poverty, food insecurity and lower access to healthcare. Rural children are also more likely to have two or more lifelong health conditions (22% vs. 20% for urban children) and are less likely to receive preventive primary care (25% vs. 21%). All-cause mortality rates are significantly higher among rural children than children in urban areas (65.1 deaths per 100,000 vs. 50.7 deaths per 100,000). Additionally, the study found that rural children are more likely to be uninsured than urban children (8.3% vs. 6.6%).”
- “The University of South Carolina Rural Health Research Center recently published a study examining differences in rural and urban child health across the United States. Among the findings, rural children are more likely than urban children to experience certain health risk factors, including poverty, food insecurity and lower access to healthcare. Rural children are also more likely to have two or more lifelong health conditions (22% vs. 20% for urban children) and are less likely to receive preventive primary care (25% vs. 21%). All-cause mortality rates are significantly higher among rural children than children in urban areas (65.1 deaths per 100,000 vs. 50.7 deaths per 100,000). Additionally, the study found that rural children are more likely to be uninsured than urban children (8.3% vs. 6.6%).”
- Nature Medicine discusses Generation gains in cognitive capacity and dementia incidence rates in Western countries, including the United States.
- Health Day tells us,
- “Smokers who have migraines carry a more than tripled risk of having a stroke in middle age or younger, a new study says.
- “Migraine sufferers who smoke had a 3.6 times higher risk of clot-related stroke by age 60 or younger, researchers reported Nov. 18 in the journal Neurology.
- “They also had a 2.6 times higher risk of stroke associated with bleeding in the brain, researchers found.
- “Further, smoking was associated with a more than doubled risk of early death whether or not a person has migraines, results showed.”
- and
- “Which is better for lowering diabetes risk — one long walk a day, or many shorter walks?
- “Lots of short walks appear to help people with excess weight achieve better control over their blood sugar, according to research published Nov. 18 in the journal Obesity.
- “Everyone in the study walked 45 minutes a day, but those who broke up their time into short bouts throughout their day had better blood sugar levels, researchers found.
- “Our findings suggest that how we distribute physical activity throughout the day may be just as important as how much we do,” corresponding author Audrey Bergouignansaid in a news release. She’s an associate professor at the University of Colorado Anschutz Medical Campus and a research director at the French National Center for Scientific Research.”
- and
- “Young adults are struggling more with uncertainty, increasing anxiety
- “Social media, school pressure and economic stress may contribute
- “Cognitive behavioral therapy can help people manage uncertainty and reduce anxiety.”
- The Wall Street Journal adds,
- “Estimated new skin-cancer cases worldwide climbed from 1.8 million in 1990 to 6.6 million in 2021, with adults ages 50 to 79 bearing the most burden.
- “The U.S. Preventive Services Task Force says there is not enough evidence to recommend for or against routine visual screening for symptom-free adults.
- “Researchers are testing whether artificial intelligence and other technologies can help identify skin cancers earlier, but effectiveness is unproven.”
- The New York Times relates,
- “Scientists believe they are one step closer to developing a blood test that could diagnose a degenerative and incurable brain disease often seen in football players, and which causes memory loss, dementia and troubling changes in behavior.
- “The disease, known as C.T.E., or chronic traumatic encephalopathy, is caused by repeated blows to the head, stalking players of contact sports as well as military personnel and victims of domestic violence.
- “For decades, the disease has been at the center of a national debate about the risks associated with football, a rite of passage for many American schoolboys. As the obituary pages filled with the names of N.F.L. superstars diagnosed with the disease, news headlines recounted a billion-dollar lawsuit players brought against the league, and a shooting spree by a former athlete who begged the authorities to “study my brain.”
- “For now, only a brain autopsy after death can confirm whether a patient had C.T.E.
- “But the authors of two recent studies hope that their findings will lead to a commercially available blood test within the next five years. That optimism, they said, was informed by successful development of a blood test for Alzheimer’s, which the Food and Drug Administration approved last year.”
- Healio adds,
- “Blood tests can provide additional info on top of CT scans, which can miss brain bleeds.
- “Levels of glial fibrillary acidic protein can distinguish patients with positive CT results from those with negative results.”
- Beckers Hospital Review lets us know,
- “Merck’s experimental cancer drug sacituzumab tirumotecan significantly improved overall survival in patients with advanced gastroesophageal cancer in a phase 3 trial.
- “The TroFuse-015 trial enrolled 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two previous lines of systemic therapy. Patients receiving the antibody-drug conjugate, also known as sac-TMT, had significantly improved overall survival compared with those receiving treatment selected by their physicians, according to a Nov. 20 news release.
- “However, the drug did not significantly improve progression-free survival. A secondary measure of tumor response was not formally tested under the trial’s prespecified analysis plan. Merck did not disclose detailed survival data and reported no new safety concerns.”
- Per BioPharma Dive,
- “Erasca said that 44% of people with KRAS-mutated pancreatic cancer responded to its experimental treatment in a small Phase 1 trial, supporting a decision to quickly advance the medicine into a Phase 3 study.
- “According to Erasca, response rates to its drug ERAS-0015 were even higher — 63% and 80%, respectively — in people with specific KRAS mutations called G12D and G12V. Those genetic signatures cover around two-thirds of people with KRAS-mutated disease. Side effects were mostly mild, and nobody quit treatment because of them, the company added.
- “While early, the data suggest Erasca’s drug could emerge as a future threat to Revolution Medicines’ breakthrough medicine Rasonque, which has already changed how pancreatic cancer is treated. Revolution’s therapy is already on the market and off to one of the best oncology launches ever. But Rasonque is associated with frequent skin rashes and its impact on G12D-mutated patients is seen as modest, leaving an opening for competitors to exploit.”
- Per Cardiovascular Business,
- “Oral semaglutide is associated with a reduced risk of heart attack, stroke or cardiovascular death for patients with type 2 diabetes, according to new findings published in JAMA Cardiology.[1] This includes both first and subsequent events.
- “Back in 2025, the SOUL clinical trial found that oral semaglutide—sold by Novo Nordisk under the brand names Wegovy and Ozempic—could help patients with type 2 diabetes lower their risk of major adverse cardiovascular events.[2] However, that study only focused on the first occurrence of an adverse event, not subsequent events. This updated analysis explored the same data, but looked at both first and subsequent major adverse cardiovascular events.
- “Total event analyses, assessing both first and subsequent events, can contribute to a better understanding of the impact of interventions on the total burden of disease,” wrote first author Nikolaus Marx, MD, a researcher with RWTH Aachen University in Germany, and colleagues.”
- Per MedPage Today,
- “A phase II study showed that two four-drug regimens that combined new agents with commonly used drugs showed promise in tuberculosis.
- “The posterior probability of superiority was 0.83 and 0.99 with the two regimens versus the standard four-drug regimen.
- “The study’s design outlines a potentially useful approach to prioritizing which regimens should be tested in phase III trials.”
From the U.S. healthcare business and artificial intelligence front.
- Healthcare Dive lets us know,
- “AI and affordability steal the show: 6 takeaways from HLTH
- “From agentic AI to GLP-1s, HLTH 2026 made one thing clear: The path from technological promise to affordable access is still a work in progress.”
- “AI and affordability steal the show: 6 takeaways from HLTH
- Beckers Health IT adds,
- “Kaiser Permanente and Massachusetts Institute of Technology researchers built AI models that use only routine EHR data to flag patients at higher risk for gestational diabetes, gestational hypertension and preeclampsia as early as 12 weeks into pregnancy, according to a study in Communications Health.
- “The team trained 49 machine learning models on 442,760 pregnancies cared for by Oakland, Calif.-based Kaiser Permanente’s Northern California region from 2011 to 2021. The models predicted seven complications at six-week intervals. At 12 weeks, they posted AUC scores of 0.80 for gestational diabetes, 0.79 for gestational hypertension and 0.74 for preeclampsia. AUC measures how well a model separates high-risk patients from low-risk ones, and a score of 1.0 is perfect.
- “Preterm birth, stillbirth, placental abruption and small-for-gestational-age births were harder to predict. Those models scored 0.62 to 0.68 even at 24 weeks.
- “The early models outperformed existing risk checklists from the National Institutes of Health and the Society for Maternal-Fetal Medicine. The researchers estimated that steering the top 20% of flagged patients into gestational diabetes lifestyle counseling would save about $10.8 million across the study’s test group. Aspirin prophylaxis for preeclampsia was also cost-effective. A cervical-length screening pathway for preterm birth was not.”
- Beckers Hospital Review identifies “Medicare’s final 2027 pay cuts, by specialty, and tells us
- “Walgreens has opened a 68,000-square-foot micro-fulfillment center in Allentown, Pa., that will support nearly 650 stores across Pennsylvania, New York, New Jersey, Maryland, Delaware and Connecticut.
- “The facility uses automation to handle routine parts of prescription fulfillment, which Walgreens says frees pharmacists and technicians in stores to spend more time on patients, according to a Nov. 18 news release. It is expected to process more than 28 million prescriptions annually and create about 185 jobs. The company also expects the facility to generate about $100,000 in annual property tax revenue and $750,000 in state and local payroll tax revenue.
- “The center follows recent openings in West Jordan, Utah, and Kent, Wash., bringing Walgreens’ micro-fulfillment network to 15 facilities supporting about 5,500 stores. Walgreens said its centers filled more than 200 million prescriptions in fiscal 2026, with volume through the centers up 20% from a year earlier, and that stores supported by the network manage about 40% of the company’s total prescription volume.”
- MedTech Dive reports,
- “Johnson & Johnson said Thursday the first hospital to commercially install and use its Ottava robotic surgery system will be Memorial Hermann-Texas Medical Center.
- “Tim Schmid, J&J’s worldwide chairman for medtech, said in a statement that the milestone is a significant step toward the company’s ambition to lead in surgical robotics.
- “The Houston-based hospital will be the first in the U.S. to use Ottava as part of J&J’s early access commercial program.”
- Fierce Pharma informs us,
- “It was a fairly flat week on the oral GLP-1 front.
- “In its 32nd week since launch, Foundayo maintained its 69K scripts from last week, according to Citi and Jefferies analysts using IQVIA data. Uptake for Lilly’s oral option continues to lag behind the Wegovy pill on raw numbers, which hit 176K scripts in its 32nd week on the U.S. market.
- “Growth for Novo’s option has slowed down, though, with Wegovy pill returning to a tally of 176K scripts last week, a 5% dip from its 185K high the week prior. Jeffries analysts noted that scripts for Novo’s injectable GLP-1s, Ozempic and Wegovy, also declined by 1% each last week.
- “The two GLP-1 giants traded a tiny amount of oral market share this week, with Novo holding 71.7%, compared to 72.8% last week, and Lilly holding 28.3%, up from 27.2% in the last weekly reporting period.”
Notable Death
- The New York Times reports,
- “Marsha Linehan, a psychologist who developed a groundbreaking therapy for people struggling with borderline personality disorder and the suicidal thoughts that often come with it — a treatment that, she later revealed, was inspired by her own struggles with the same condition as a young adult — died on Nov. 10 in Seattle. She was 83.
- “Her death from complications of pneumonia, in hospice care, was announced by the Linehan Institute, which she founded to spread information and training about the treatment, dialectical behavior therapy, or D.B.T.
- “Borderline personality disorder is characterized by an inability to control one’s emotions, and often manifests in mood swings, unstable behavior, unstable relationships and self-harm, including suicidal thoughts.
- “Until Dr. Linehan developed her treatment in the early 1990s, therapists were wary of working with clients with borderline personality disorder — they were more likely to die by suicide, to sue therapists or to impose unreasonable demands on the therapeutic relationship.”
- RIP
